New drug duo aims to boost immune attack on tough head and neck cancers
Disease control
Not yet recruiting
This early-stage study is testing whether adding an experimental drug called decitabine can make an approved immunotherapy (nivolumab) work better against recurrent or spreading head and neck cancer. The main goals are to find the safest dose of the combination and see how it aff…
Phase: PHASE1 • Sponsor: Kyunghee Burkitt, DO, PhD • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC